Wang Shuo, Wei Xing, Chen Bingyao, Zhao Min, Song Guangze, Zhang Zengliang, Li Nan
Department of Orthopedic Oncology, the First Affiliated Hospital of Chinese People's Liberation Army General Hospital, Beijing 100048, P.R. China.
Department of Pathology, the First Affiliated Hospital of Chinese People's Liberation Army General Hospital, Beijing 100048, P.R. China.
Mol Clin Oncol. 2016 Jan;4(1):65-69. doi: 10.3892/mco.2015.661. Epub 2015 Oct 23.
Metabotropic glutamate receptor 4 (mGluR4) has been associated with the pathogenesis of osteosarcoma. The aim of this study was to investigate mGluR4 expression and its clinical significance in osteosarcoma patients. mGluR4 expression was investigated using immunohistochemistry (IHC) in 58 osteosarcomas and 32 giant-cell tumors of bone. The correlations between mGluR4 expression and clinicopathological characteristics were analyzed with the Chi-squared test and survival curves were generated using the Kaplan-Meier method. The IHC results demonstrated that 20.69% (12/58) of the osteosarcomas and 43.75% (14/32) of the giant-cell tumors were mGluR4-positive. The statistical analysis revealed that mGluR4 expression was correlated with gender, age, Enneking stage and tumor volume in osteosarcomas (P<0.05). In the multivariate stepwise Cox regression analysis, Enneking stage was found to be statistically significantly associated with survival (P<0.05) and the survival analysis demonstrated that the survival probability was significantly higher in patients with higher mGluR4 expression compared with those with lower expression (P<0.05). Therefore, mGluR4 expression may be used to estimate the prognosis of osteosarcoma patients.
代谢型谷氨酸受体4(mGluR4)与骨肉瘤的发病机制有关。本研究的目的是调查骨肉瘤患者中mGluR4的表达及其临床意义。采用免疫组织化学(IHC)方法检测了58例骨肉瘤和32例骨巨细胞瘤中mGluR4的表达。采用卡方检验分析mGluR4表达与临床病理特征之间的相关性,并采用Kaplan-Meier法绘制生存曲线。免疫组化结果显示,20.69%(12/58)的骨肉瘤和43.75%(14/32)的骨巨细胞瘤mGluR4呈阳性。统计分析显示,骨肉瘤中mGluR4表达与性别、年龄、Enneking分期和肿瘤体积相关(P<0.05)。在多因素逐步Cox回归分析中,发现Enneking分期与生存有统计学显著相关性(P<0.05),生存分析表明,mGluR4高表达患者的生存概率显著高于低表达患者(P<0.05)。因此,mGluR4表达可用于评估骨肉瘤患者的预后。